Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,291.34 +7.94 (+0.15%) Dow
38,711.29 +140.26 (+0.36%) Nasdaq
16,857.05 +28.38 (+0.17%) Bitcoin USD
70,878.37 +2,174.24 (+3.16%) CMC Crypto 200
1,507.80 +34.05 (+2.31%)
Novo Nordisk A/S (0QIU.IL)
| Previous close | 927.20 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 930.04 - 930.04 |
| 52-week range | 86.66 - 943.00 |
| Volume | |
| Avg. volume | 1,005,235 |
| Market cap | 3.905T |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 62.59 |
| EPS (TTM) | 14.86 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 7.08 (1.04%) |
| Ex-dividend date | 18 Aug 2023 |
| 1y target est | N/A |
GuruFocus.comWilliam Blair Commentary: Waistlines and GLP1-s--Expanding in Unison
By Thomas A. Sternberg, CFA, Partner and Dasha Fomina
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
PR NewswireNovo Nordisk launches national Wegovy® campaign, Power of Wegovy®
Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.
